Abstract Background Acute pancreatitis (AP) is one of the serious complications among patients with hematopoietic stem cell transplantation (HSCT). We aimed to evaluate the impact of AP on hospitalization outcomes in pediatric HSCT recipients. Methods We retrospectively queried the PHIS database to include all pediatric patients who underwent HSCT between 2005-2024. The study population was divided into those with and without AP, and compared for various demographic and clinical variables. The primary outcome was in-hospital mortality, and secondary outcomes included healthcare resource utilization. Results A total of 33,439 HSCT recipients were identified, and the prevalence rate of AP was 1.1%. The AP group had a significantly higher in-hospital mortality rate (22.7% vs. 4.6%), higher median hospitalization costs (USD 698,372 vs. 187,583), and higher median length of stay (138.5 vs. 60 days) (all p 10, with an AUC of 0.85 (95% CI: 0.84 to 0.88). Conclusion AP in HSCT prognosticates adverse outcomes with increased in-hospital mortality, prolonged length of stay, and higher hospitalization costs. Clinicians need to be vigilant in preventing and aggressively managing AP in HSCT. Category of study Population study Impact Acute pancreatitis (AP) in pediatric hemopoietic stem cell transplant (HSCT) recipients prognosticates adverse outcomes with increased mortality, prolonged length of stay, and higher hospitalization costs. The risk stratification model predicted a 2.7 (95% CI: 2.2 to 3.4) times increased risk of AP for a score of >10, with an AUC of 0.85 (95% CI: 0.84 to 0.88). Multivariable analysis showed AP was associated with 1.5 (CI:1.2 to 2, p = 0.001) times increased risk of mortality in pediatric population.
Thavamani et al. (Fri,) studied this question.